Skip to content

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Biosimilar Approval Status
Home
- Home
About BR&R
News and Commentary
BR&R Manufacturer Profiles
- Amneal Biosciences
- Samsung Bioepis
Contact Us

$0.00 0 items

Alvotech-logo

Stanton Mehr August 6, 2020

Published by Stanton Mehr

View all posts by Stanton Mehr

Published August 6, 2020

Post navigation

Previous Post A Profile of a Lesser-Known Player in the Biosimilar Space: Alvotech

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search for:

Recent Posts

Samsung Bioepis, Sandoz Forge Deeper Biosimilar Ties March 19, 2026
As Oncology Biosimilar Acquisition Prices Fall for Hospitals, Biosimilar Adoption Rises March 16, 2026
The FDA’s New Draft Guidance Contributes to Streamlined Biosimilar Development March 12, 2026
Two Leaders’ Views on National PBM Reform: Biosimilar and ERISA Benefits March 9, 2026
Deeper Views on TrumpRx (the Direct-to-Patient Channel), MFN and MFP, and Biosimilars March 5, 2026
A Filgrastim Biosimilar Approval, and a Bevacizumab Rejection February 27, 2026
Will National PBM Reform Whither Away the Private-Label Channel? February 23, 2026
Navigating Biosimilar Substitution February 18, 2026
Update on Amgen’s Pavblu Launch Success February 13, 2026
The Biosimilar on TrumpRx: Pfizer Offering Further Discounts on Abrilada February 6, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Top Posts & Pages

Samsung Bioepis Manufacturer Profile Page FINAL
The Evolution of the Biosimilars Market
Biosimilar Approval Status
Celltrion Gains First Omalizumab Biosimilar Approval
As Oncology Biosimilar Acquisition Prices Fall for Hospitals, Biosimilar Adoption Rises
Availability of Top Ranibizumab Biosimilar May be Paused
Biosimilar Clinical Trial Costs in Terms of Expense and Time
A New Wave of Ustekinumab Biosimilar Launches, Discounted up to 90%
The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
Samsung Bioepis, Sandoz Forge Deeper Biosimilar Ties

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

X
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions
Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.